DeCure for Multiple mitochondrial dysfunctions syndrome 1
DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for multiple mitochondrial dysfunctions syndrome 1 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMultiple mitochondrial dysfunctions syndrome 1 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for multiple mitochondrial dysfunctions syndrome 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
No abstract in this set reports a clinical trial or patient outcome for multiple mitochondrial dysfunctions syndrome 1. The 2010 review states that mitochondrially-targeted therapeutics that have reached clinical trials have produced encouraging but largely inconclusive results. The 2020 review notes that patients with mitochondrial diseases are usually treated with supportive and symptomatic therapies due to the absence of a specific disease-modifying therapy. The 1999 and 2015 papers discuss general mitochondrial biology and the history of mitochondrial medicine but provide no data on any drug tested in this specific syndrome.
No concrete numbers — survival, response rates, or sample sizes — are given for any intervention in multiple mitochondrial dysfunctions syndrome 1 across these abstracts. The 2020 review mentions that management is based on early treatment of organ-specific complications and avoidance of catabolic stressors or toxic medication, but this is general guidance, not evidence of efficacy. The 2010 review explicitly calls the clinical trial results inconclusive.
What is still missing for this disease: any dedicated clinical trial data, any drug that has been tested in patients with multiple mitochondrial dysfunctions syndrome 1, and any patient-stratification strategy that might identify responders. The field lacks both funding for a disease-specific trial and a validated outcome measure for this ultra-rare condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Expert Opinion on Therapeutic Targets · 2010 · 82 citations
Targeting mitochondrial dysfunction in neurodegenerative disease: Part II
AbstractIMPORTANCE OF THE FIELD: With improvements in life expectancy over the past decades, the incidence of neurodegenerative disease has dramatically increased and new therapeutic strategies are urgently needed. One possible approach is to target mitochondrial dysfunction, which has been implicated in the pathogenesis of numerous neurodegenerative disorders. AREAS COVERED IN THIS REVIEW: This review examines the role of mitochondrial dysfunction in neurodegeneration, drawing examples from common diseases such as Alzheimer's disease and rarer familial disorders such as Charcot-Marie-Tooth. The review is provided in two parts. In part I we discussed the mitochondrial defects which have been most extensively researched (oxidative stress, bioenergetic dysfunction, calcium mishandling). We focus now on those defects which have more recently been implicated in neurodegeneration; in mitochondrial fusion/fission, protein import, protein quality control, kinase signalling and opening of the permeability transition pore. WHAT THE READER WILL GAIN: An examination of mitochondrial defects observed in neurodegeneration, and existing and possible future therapies to target these defects. TAKE HOME MESSAGE: The mitochondrially-targeted therapeutics that have reached clinical trials so far have produced encouraging but largely inconclusive results. Increasing understanding of mitochondrial dysfunction has, however, led to preclinical work focusing on novel approaches, which has generated exciting preliminary data.
Oxford University Press eBooks · 2015 · 78 citations
Mitochondrial diseases
AbstractThis chapter critiques ten seminal papers that epitomize the advent and evolution of mitochondrial medicine from the latter half of the last century up until today. These important bodies of work span the pre-molecular and molecular eras, from when diagnostic yield was based on meticulous clinical and biochemical characterization of patients, up until now, with targeted next-generation sequencing revolutionizing our diagnostic approach. The first clinical description of a mitochondrial disorder is reviewed and the subsequent landmark papers that define current clinical and molecular understanding of human diseases caused by inherited disorders of mitochondrial dysfunction are chronicled. The chapter also charts the shift in emphasis from diagnosis to the development of treatments and novel approaches for disease prevention.
Journal of Clinical Medicine · 2020 · 14 citations · open access
Therapeutical Management and Drug Safety in Mitochondrial Diseases—Update 2020
AbstractMitochondrial diseases (MDs) are a group of genetic disorders that may manifest with vast clinical heterogeneity in childhood or adulthood. These diseases are characterized by dysfunctional mitochondria and oxidative phosphorylation deficiency. Patients are usually treated with supportive and symptomatic therapies due to the absence of a specific disease-modifying therapy. Management of patients with MDs is based on different therapeutical strategies, particularly the early treatment of organ-specific complications and the avoidance of catabolic stressors or toxic medication. In this review, we discuss the therapeutic management of MDs, supported by a revision of the literature, and provide an overview of the drugs that should be either avoided or carefully used both for the specific treatment of MDs and for the management of comorbidities these subjects may manifest. We finally discuss the latest therapies approved for the management of MDs and some ongoing clinical trials.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
